Glycine and Keppra drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Glycine (glycine) and Keppra (levetiracetam). Common drug interactions include accident among females and somnolence among males.

The phase IV clinical study analyzes what interactions people have when they take Glycine and Keppra. It is created by eHealthMe based on reports of 16 people who take the same drugs from the FDA, and is updated regularly.

What is Glycine?

Glycine has active ingredients of glycine. eHealthMe is studying from 1,063 Glycine users. Check the latest studies of Glycine.

What is Keppra?

Keppra has active ingredients of levetiracetam. It is often used in epilepsy. eHealthMe is studying from 73,504 Keppra users. Check the latest studies of Keppra.

On Jul, 14, 2026

16 people who take Glycine and Keppra together, and have interactions are studied.

What are the common drug interactions of Glycine and Keppra, by gender? *:

female:

Accident
Headache (pain in head)
Depressed level of consciousness
Drug ineffective
Oculomucocutaneous syndrome (a condition characterized by keratoconjunctivitis sicca and by scarring, fibrosis, metaplasia, and shrinkage of the conjunctiva;)
Pneumonia
Rash
Sopor (sleep)
Status epilepticus (a life-threatening condition in which the brain is in a state of persistent seizure)
Stevens-johnson syndrome (an immune-complex-mediated hypersensitivity disorder. it ranges from mild skin and mucous membrane lesions to a severe)

male:

Somnolence (a state of near-sleep, a strong desire for sleep)
Arthralgia (joint pain)
Hyperkeratosis (thickening of the outer layer of the skin)
Hypoaesthesia (reduced sense of touch or sensation)
Intra-abdominal haemorrhage (intra-abdominal bleeding)
Joint contracture (a permanent shortening of a muscle or joint)
Joint range of motion decreased (disease of joint movement)
Mobility decreased (ability to move is reduced)
Musculoskeletal stiffness (stiffness of the body's muscles, joints, tendons, ligaments and nerves)
Nephrogenic systemic fibrosis (involves fibrosis of skin, joints, eyes due to kidney disease)

What are the common drug interactions of Glycine and Keppra, by age (0-1 to 60+)? *:

0-1:

Feeding disorder (when children refuse to eat certain food groups)
Maternal exposure during pregnancy (use of substance during pregnancy)
Premature baby
Somnolence (a state of near-sleep, a strong desire for sleep)

2-9:

n/a

10-19:

n/a

20-29:

n/a

30-39:

Blood creatine phosphokinase increased
Initial insomnia (feeling of inadequate or poor-quality sleep)
Insomnia (sleeplessness)
Somnolence (a state of near-sleep, a strong desire for sleep)

40-49:

Drug ineffective
Hepatitis c
Intra-abdominal haemorrhage (intra-abdominal bleeding)
Oculomucocutaneous syndrome (a condition characterized by keratoconjunctivitis sicca and by scarring, fibrosis, metaplasia, and shrinkage of the conjunctiva;)
Abdominal compartment syndrome (increased pressure in abdomen)

50-59:

Arthralgia (joint pain)
Deformity (disfigurement)
Mobility decreased (ability to move is reduced)
Musculoskeletal stiffness (stiffness of the body's muscles, joints, tendons, ligaments and nerves)
Nephrogenic systemic fibrosis (involves fibrosis of skin, joints, eyes due to kidney disease)
Oedema (fluid collection in tissue)
Oedema peripheral (superficial swelling)
Pain
Pain in extremity
Pain of skin

60+:

n/a

What are the existing conditions these people have? *

Seizures (abnormal excessive or synchronous neuronal activity in the brain): 4 people, 25.00%
Nuclear Magnetic Resonance Imaging Brain: 3 people, 18.75%
High Blood Pressure: 3 people, 18.75%
Hepatitis C: 3 people, 18.75%
Disease Complication: 3 people, 18.75%
Hiv Infection: 3 people, 18.75%
Hepatic Cirrhosis (chronic liver disease characterized by replacement of liver tissue by fibrosis, scar tissue): 3 people, 18.75%
Agitation (state of anxiety or nervous excitement): 2 people, 12.50%
Cataplexy (loss of muscle tone accompanied by full conscious awareness): 2 people, 12.50%
Status Epilepticus (a life-threatening condition in which the brain is in a state of persistent seizure): 2 people, 12.50%

* Approximation only. Some reports may have incomplete information.

Do you take Glycine and Keppra?

- Personalize this study to your gender, age, symptoms and drugs
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously